ArticlePLoS pathogens2021
A host receptor enables type 1 pilus-mediated pathogenesis of Escherichia coli pyelonephritis.
Article in PLoS pathogens, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 42 citations in OpenAlex.
- Urinary tract infections in children.Nature reviews. Urology · 2026Review
- Single-nucleus transcriptomics illuminates sex differences during murine Escherichia coli pyelonephritis.Communications biology · 2026Article
- Molecular mechanisms of acute inflammation: systemic responses and kidney-specific pathophysiology.Function (Oxford, England) · 2026Review
- Uropathogenic Escherichia coli invade luminal prostate cells via FimH-PPAP receptor binding.Nature microbiology · 2026Article
- Maximizing bacterial survival: integrating sense-and-respond and bet-hedging mechanisms.Trends in microbiology · 2025Review
- Single-nucleus transcriptomics illuminates sex differences during murine Escherichia coli pyelonephritis.Research square · 2025Article
- Monoclonal antibodies targeting the FimH adhesin protect against uropathogenicScience advances · 2025Article
- LDL receptor-mediated endocytosis ofProceedings of the National Academy of Sciences of the United States of America · 2025Article
- Bacterial adhesion strategies and countermeasures in urinary tract infection.Nature microbiology · 2025Review
- Current and emerging strategies to curb antibiotic-resistant urinary tract infections.Nature reviews. Urology · 2024Review
- Conformational ensembles inProceedings of the National Academy of Sciences of the United States of America · 2024Article
- T3SS protein EsrC binds to theApplied and environmental microbiology · 2024Article
- Medical Device-Associated Biofilm Infections and Multidrug-Resistant Pathogens.Pathogens (Basel, Switzerland) · 2024Review
- Intercalated cell function, kidney innate immunity, and urinary tract infections.Pflugers Archiv : European journal of physiology · 2024Review
- Discovery of Orally Bioavailable FmlH Lectin Antagonists as Treatment for Urinary Tract Infections.Journal of medicinal chemistry · 2024Article
- Uropathogen and host responses in pyelonephritis.Nature reviews. Nephrology · 2023Review
- Immune defenses in the urinary tract.Trends in immunology · 2023Review
- Article
- Dynamics of Urinary Extracellular DNA in Urosepsis.Biomolecules · 2023Article
- FimH and Type 1 Pili Mediated Tumor Cell Cytotoxicity by UropathogenicPathogens (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
Abstract
Type 1 pili have long been considered the major virulence factor enabling colonization of the urinary bladder by uropathogenic Escherichia coli (UPEC). The molecular pathogenesis of pyelonephritis is less well characterized, due to previous limitations in preclinical modeling of kidney infection. Here, we demonstrate in a recently developed mouse model that beyond bladder infection, type 1 pili also are critical for establishment of ascending pyelonephritis. Bacterial mutants lacking the type 1 pilus adhesin (FimH) were unable to establish kidney infection in male C3H/HeN mice. We developed an in vitro model of FimH-dependent UPEC binding to renal collecting duct cells, and performed a CRISPR screen in these cells, identifying desmoglein-2 as a primary renal epithelial receptor for FimH. The mannosylated extracellular domain of human DSG2 bound directly to the lectin domain of FimH in vitro, and introduction of a mutation in the FimH mannose-binding pocket abolished binding to DSG2. In infected C3H/HeN mice, type 1-piliated UPEC and Dsg2 were co-localized within collecting ducts, and administration of mannoside FIM1033, a potent small-molecule inhibitor of FimH, significantly attenuated bacterial loads in pyelonephritis. Our results broaden the biological importance of FimH, specify the first renal FimH receptor, and indicate that FimH-targeted therapeutics will also have application in pyelonephritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.